Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: Lessons from the REDUCE study

BJU International

Volumn 109, Issue 8, 2012, Pages 1162-1169

  Marberger, Michael ^a   Freedland, Stephen J ^b   Andriole, Gerald L ^c   Emberton, Mark ^d   Pettaway, Curtis ^e   Montorsi, Francesco ^f   Teloken, Claudio ^g   Rittmaster, Roger S ^h   Somerville, Matthew C ^h   Castro, Ramiro ^h  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b DUKE UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^g UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^h GLAXOSMITHKLINE   (United States)

Author keywords

5 reductase inhibitor; Dutasteride; Performance; Prostate specific antigen; REDUCE study

Indexed keywords

DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK REDUCTION; SENSITIVITY AND SPECIFICITY;

5-ALPHA REDUCTASE INHIBITORS; AGED; AZASTEROIDS; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOSONOGRAPHY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84859468440     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10373.x     Document Type: Article

References (15)

1. Andriole GL, Bostwick D, Brawley OW et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2010; 185: 126-31
2. Thompson IM, Chi C, Ankerst DP et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98: 1128-33 (Pubitemid 44288787)
3. Andriole GL, Guess HA, Epstein JI et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1998; 52: 195-201; discussion 201-2
4. Andriole GL, Humphrey P, Ray P et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004; 172: 915-9 (Pubitemid 39096422)
5. Thompson IM, Pauler Ankerst D, Chi C et al. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol 2007; 25: 3076 -81
6. American Urological Association. Prostate-Specific Antigen. Best Practice Statement: 2009 Update. 2009. Available at: http://www.auanet.org/content/ media/psa09.pdf. Accessed 10 Feburary 2011
7. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Prostate Cancer Early Detection, USA. 2010. Version 2.
8. Andriole G, Bostwick D, Brawley O et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004; 172: 1314-7 (Pubitemid 39249705)
9. Andriole GL, Bostwick DG, Brawley OW et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-202
10. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-74 (Pubitemid 24037911)
11. Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011; 103: 462-9
12. Marberger M, McConnell JD, Fowler I et al. Biopsy misidentification identified by DNA profiling in a large multicenter trial. J Clin Oncol 2011; 29: 1744-9
13. Tanguay S, Awde M, Brock G et al. Diagnosis and management of benign prostatic hyperplasia in primary care. Can Urol Assoc J 2009; 3: S92-100
14. Slev PR, La'ulu SL, Roberts WL. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA. Am J Clin Pathol 2008; 129: 952-8
15. Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol 2006; 176: 868-74 (Pubitemid 44142551)